Clinical Trial Update: Topical Everolimus in Patients With Tuberous Sclerosis Complex [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial for topical everolimus in facial angiofibromas associated with tuberous sclerosis complex was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facial Angiofibromas
• Tuberous Sclerosis Complex

Drugs mentioned

• topical everolimus (everolimus)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Facial Angiofibromas | Phase 2, Phase 3 | Status: WITHDRAWN